Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 4/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176454 | 1.00 | ADRA1A (0.42) | ADRA1AHTR3AADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL3184832 | 0.98 | ADRA1A (0.41) | ADRA1AHTR3AADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL3184840 | 0.98 | ADRA1A (0.41) | ADRA1AHTR3AADRA2AADRA2BADRA2C | |
| Sulfuric Acid SCHEMBL7331483 | 0.94 | ADRA1A (0.38) | ADRA1AHTR3AADRA2AADRA2BADRA2C | |
| SCHEMBL6851022 | 0.87 | ADRA1A (0.53) | ADRA1AHTR3AADRA2AADRA2BADRA2C | |
| SCHEMBL13531389 | 0.85 | HTR3A (0.42) | ADRA1AHTR3AADRA2AADRA2BADRA2C | |
| SCHEMBL3185647 | 0.85 | ADRA1A (0.40) | ADRA1AHTR3AADRA2AADRA2BADRA2C | |
| SCHEMBL13531413 | 0.85 | HTR3A (0.42) | ADRA1AHTR3AADRA2AADRA2BADRA2C | |
| SCHEMBL7332677 | 0.85 | HTR3A (0.39) | ADRA1AHTR3AADRA2AADRA2BADRA2C | |
| SCHEMBL3185643 | 0.85 | ADRA1A (0.40) | ADRA1AHTR3AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652052-B2 | Process for producing ramosetron or its salt | ASTELLAS PHARMA INC. (JP) | 2010-01-26 | — | — | US | claimed |
| US-20090069570-A1 | Novel Process for Producing Ramosetron or Its Salt | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | claimed |
| EP-1870408-A1 | NOVEL PROCESS FOR PRODUCING RAMOSETRON OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-12-26 | — | — | EP | claimed |
| US-7652052-B2 | Process for producing ramosetron or its salt | ASTELLAS PHARMA INC. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090069570-A1 | Novel Process for Producing Ramosetron or Its Salt | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1870408-A1 | NOVEL PROCESS FOR PRODUCING RAMOSETRON OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069570-A1 | Novel Process for Producing Ramosetron or Its Salt | SI, VIP, HTR1D | ADRA1A 131/4885HTR3A 101/4885ADRA2A 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.